A nutrient-dense citrus fruit with modest, limited benefits. The strongest human evidence shows a small lowering of blood pressure and a population link to lower mouth-and-throat cancer risk. Its defining issue is changing how the body handles many medications for up to three days, which dominates the risk picture for anyone on common drugs. (Full Review)

Protocol

Standard intake

Half a grapefruit or ~250 mL juice before meals

One to three times daily, as used in pre-meal grapefruit trials

Whole fruit versus juice

Whole fruit favored over juice

Retains fiber, blunts blood-sugar rise; juice has higher interaction potential

Single versus split doses

Split across meals

Supports satiety and avoids a large one-time furanocoumarin bolus

Time to effect

Blood pressure & lipids

4–12 weeks

Changes emerge over weeks of regular intake

Drug interactions

Within hours

Appear within hours of a single serving

Benefits

Medium: Modest systolic blood pressure reduction; lower risk of oral and pharyngeal cancer

Low: Improved lipid profile; improved insulin sensitivity and weight management support

Speculative: Neuroprotection and cognitive support; general antioxidant and longevity effects

Contraindications

People taking any of the interacting medications

Advanced chronic kidney disease (eGFR <30, CKD stage 4–5)

Personal history of melanoma consuming large quantities

Key Interactions

Statins (simvastatin, atorvastatin)

Calcium-channel blockers (felodipine, nifedipine, nisoldipine)

Immunosuppressants (cyclosporine, tacrolimus, sirolimus)

Anti-arrhythmics and others (amiodarone, dronedarone, certain antihistamines)

Drugs whose absorption is reduced, OATP substrates (fexofenadine, aliskiren, celiprolol)

Over-the-counter medications (some antihistamines, dextromethorphan)

Supplement interactions

Other CYP3A4 inhibitors (ketoconazole, ritonavir)

Risk & Side Effects

High: Drug interactions via CYP3A4 inhibition; reduced absorption of certain drugs via OATP inhibition

Medium: Possible increased melanoma risk at high intake

Low: Dental enamel erosion; gastrointestinal and reflux effects

Speculative: Excess potassium in vulnerable individuals

Monitoring

Marker	Target	Why
Systolic Blood Pressure	110–120 mmHg	Tracks grapefruit's main measurable cardiovascular benefit
LDL Cholesterol	<100 mg/dL (lower if higher risk)	Detects any lipid improvement and flags statin-interaction concerns
Triglycerides	<100 mg/dL	Red grapefruit may modestly lower this
Potassium	4.0–4.5 mmol/L	Guards against accumulation in kidney-impaired or potassium-sparing-drug users
eGFR (kidney function)	>90 mL/min/1.73m²	Identifies those at higher risk from potassium and drug interactions

Cadence: Blood pressure at home over the first 4–8 weeks; recheck a lipid panel at 8–12 weeks; review interacting-drug levels per the prescribing clinician's schedule, then every 6–12 months thereafter

Qualitative Assessment

Energy levels and post-meal satiety when grapefruit is eaten before meals
Any new muscle aches or weakness (a warning sign of a statin interaction)
Reflux or heartburn frequency
Skin sensitivity to sun in high-volume consumers

Grapefruit for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment